| Chapter title |
Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation
|
|---|---|
| Chapter number | 28 |
| Book title |
Exon Skipping and Inclusion Therapies
|
| Published in |
Methods in molecular biology, September 2018
|
| DOI | 10.1007/978-1-4939-8651-4_28 |
| Pubmed ID | |
| Book ISBNs |
978-1-4939-8650-7, 978-1-4939-8651-4
|
| Authors |
Tejal Aslesh, Rika Maruyama, Toshifumi Yokota, Aslesh, Tejal, Maruyama, Rika, Yokota, Toshifumi |
| Abstract |
Spinal muscular atrophy (SMA) is the most common genetic cause of infantile death caused by mutations in the SMN1 gene. Nusinersen (Spinraza), an antisense therapy-based drug with the 2'-methoxyethoxy (2'MOE) chemistry approved by the FDA in 2016, brought antisense drugs into the spotlight. Antisense-mediated exon inclusion targeting SMN2 leads to SMN protein expression. Although effective, 2'MOE has weaknesses such as the inability to cross the blood-brain barrier and the high cost of treatment. To investigate new chemistries of antisense oligonucleotides (ASOs), SMA mouse models can serve as an important source. Here we describe methods to test the efficacy of ASOs, such as phosphorodiamidate morpholino oligomers (PMOs), in a severe SMA mouse model. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 33% |
| Student > Master | 2 | 10% |
| Unspecified | 1 | 5% |
| Student > Bachelor | 1 | 5% |
| Student > Doctoral Student | 1 | 5% |
| Other | 2 | 10% |
| Unknown | 7 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 3 | 14% |
| Medicine and Dentistry | 3 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 10% |
| Economics, Econometrics and Finance | 1 | 5% |
| Other | 3 | 14% |
| Unknown | 7 | 33% |